The study tested a new platform that targets the virus’ internal proteins rather than its rapidly changing surface antigens. The OHSU team used a vaccine based on the 1918 influenza virus to test their approach. Developed using a CMV-based platform previously used in HIV research, the vaccine induced a strong immune response in nonhuman primates exposed to the modern H5N1 avian influenza virus.
Senior author John Sucha emphasized that the vaccine could provide long-lasting immunity. This approach shifts the focus from current vaccines, which must adapt to changing viral strains by targeting stable, internal components of the virus using T cells.
The research paves the way for a vaccine against any flu “within the next five to 10 years.”
News materials are not equivalent to a doctor’s prescription. Consult a specialist before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
